Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted inducement awards to seven newly hired employees as of November 30, 2025 under its 2022 Inducement Stock Incentive Plan.

The company issued stock options to purchase an aggregate of 2,800 shares at an exercise price of $5.62 (closing price on the Grant Date) and granted an aggregate of 15,791 restricted stock units (RSUs). Options vest over four years (25% after one year, then monthly 1/48th), and RSUs vest over three years (33 1/3% each year), each subject to continued service.

News Market Reaction

-6.78%

9 alerts

-6.78% News Effect

+18.3% Peak in 2 hr 55 min

-$8M Valuation Impact

$105M Market Cap

0.9x Rel. Volume

On the day this news was published, KPTI declined 6.78%, reflecting a notable negative market reaction. Argus tracked a peak move of +18.3% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $105M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 2,800 shares RSUs granted: 15,791 RSUs Option exercise price: $5.62 per share +5 more

8 metrics

Stock options granted 2,800 shares Inducement stock option grants as of Nov 30, 2025

RSUs granted 15,791 RSUs Inducement awards to seven newly hired employees

Option exercise price $5.62 per share Closing price on the Nov 30, 2025 Grant Date

Option vesting period 4 years 25% after one year, then 1/48th monthly

Initial cliff vest 25% Portion of options vesting on one-year anniversary

Monthly vesting rate 1/48th of options Monthly vesting after first anniversary

RSU vesting period 3 years Inducement RSUs vesting annually

Annual RSU vesting tranche 33 1/3% Portion of RSUs vesting on each Grant Date anniversary

Market Reality Check

Price: $5.95 Vol: Volume 596,389 is 4.28x t...

high vol

$5.95 Last Close

Volume Volume 596,389 is 4.28x the 20-day average of 139,212, indicating elevated trading activity before this filing. high

Technical Shares at $7.00 were trading above the $5.48 200-day moving average and sat 43.78% below the 52-week high and 99.43% above the 52-week low.

Peers on Argus

KPTI was up 1.41% while close biotech peers showed mixed moves: CUE (-0.94%), PY...

KPTI was up 1.41% while close biotech peers showed mixed moves: CUE (-0.94%), PYPD (-1.49%), APLT (-1.77%) declined, whereas CAMP (+10.89%) and MAIA (+12.33%) gained. This pattern points to stock-specific factors rather than a uniform sector rotation.

Historical Context

5 past events · Latest: Dec 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Conference participation	Neutral	+2.4%	Announcement of virtual fireside chat in Baird’s Biotech Discovery Series.
Dec 01	Inducement grants	Neutral	-6.8%	Disclosure of stock options and RSUs granted to seven new employees.
Dec 01	Conference participation	Neutral	+2.3%	Planned fireside chat at Piper Sandler healthcare conference in New York.
Nov 03	Inducement grant	Neutral	+4.7%	Grant of 800 RSUs to a new hire under inducement plan.
Nov 03	Earnings update	Negative	+4.7%	Q3 2025 results with net loss and going‑concern discussion alongside guidance.

Pattern Detected

Recent news often produced sizable moves that did not clearly match the benign tone of the announcements, especially around inducement grants and financing-related disclosures.

Recent Company History

Over the last few months, Karyopharm’s news flow mixed corporate events, financing activity, and operational updates. Inducement grants on Nov 3 and Dec 1 under the 2022 Inducement Plan were routine but saw share moves of +4.66% and -6.78%. Conference participation in early December drew modest gains. The Q3 2025 earnings release on Nov 3, including going‑concern language and detailed guidance, coincided with a +4.66% move. Overall, price reactions have frequently diverged from the neutral-to-mixed tone of the releases.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration dated Nov 3, 2025 covers up to 2,805,688 existing and warrant-linked shares for sale by current stockholders. The company is not selling new securities under this registration and does not receive proceeds from these resales, aside from potential cash if outstanding warrants are exercised.

Market Pulse Summary

The stock moved -6.8% in the session following this news. A negative reaction despite routine induce...

Analysis

The stock moved -6.8% in the session following this news. A negative reaction despite routine inducement grants would fit a pattern where stock moves have sometimes diverged from neutral news, as seen around prior inducement announcements. The shares were trading above the 200-day moving average with volume running at 4.28x the 20-day average before this filing, so position‑cleaning or sensitivity to equity-related headlines could have amplified pressure. Existing resale registrations covering 2,805,688 shares by selling stockholders may also remain in focus.

Key Terms

nasdaq listing rule 5635(c)(4), stock option, restricted stock units (rsus), exercise price, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock option financial

"granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

restricted stock units (rsus) financial

"an aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

exercise price financial

"The stock options have an exercise price of $5.62 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vest over four years, with 25% of the total number of shares underlying the stock options vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an  aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees. These awards were granted as of November 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $5.62 per share, the closing price of Karyopharm's common stock on the Grant Date and vest over four years, with 25% of the total number of shares underlying the stock options vesting on the one-year anniversary of the employee's commencement date and 1/48th of the total number of shares vesting monthly thereafter, subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. 

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302629473.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What inducement awards did Karyopharm (KPTI) grant on November 30, 2025?

Karyopharm granted options for an aggregate of 2,800 shares and 15,791 RSUs to seven newly hired employees, effective November 30, 2025.

What is the exercise price of the KPTI stock options granted as inducements?

The exercise price is $5.62 per share, equal to Karyopharm's closing price on the Grant Date.

How do the KPTI stock options vest for the November 30, 2025 grants?

Options vest over four years: 25% after one year, then 1/48th monthly thereafter, subject to continued service.

What is the vesting schedule for the RSUs KPTI awarded to new hires?

Each RSU award vests over three years with 33 1/3% vesting each year, subject to continued service.

Why were the inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as inducements material to new employees entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4).